Your browser is no longer supported. Please, upgrade your browser.
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E9.92 EPS (ttm)62.64 Insider Own2.00% Shs Outstand106.20M Perf Week0.86%
Market Cap66.07B Forward P/E12.92 EPS next Y48.08 Insider Trans-18.21% Shs Float102.56M Perf Month2.40%
Income7.00B PEG0.76 EPS next Q18.70 Inst Own87.70% Short Float1.60% Perf Quarter9.14%
Sales13.54B P/S4.88 EPS this Y65.30% Inst Trans0.48% Short Ratio2.20 Perf Half Y5.98%
Book/sh162.50 P/B3.82 EPS next Y-31.81% ROA34.90% Target Price704.58 Perf Year15.55%
Cash/sh54.43 P/C11.42 EPS next 5Y13.00% ROE50.50% 52W Range441.00 - 686.62 Perf YTD-1.60%
Dividend- P/FCF12.28 EPS past 5Y40.80% ROI23.90% 52W High-9.50% Beta0.19
Dividend %- Quick Ratio3.30 Sales past 5Y15.70% Gross Margin86.60% 52W Low40.91% ATR15.44
Employees9123 Current Ratio3.70 Sales Q/Q50.50% Oper. Margin55.20% RSI (14)49.33 Volatility2.35% 2.14%
OptionableYes Debt/Eq0.16 EPS Q/Q93.80% Profit Margin51.70% Rel Volume1.76 Prev Close614.38
ShortableYes LT Debt/Eq0.11 EarningsFeb 04 BMO Payout0.00% Avg Volume743.45K Price621.40
Recom2.10 SMA20-0.04% SMA50-1.79% SMA2006.16% Volume1,309,589 Change1.14%
Jan-05-22Downgrade BofA Securities Neutral → Underperform $675 → $575
Jan-03-22Upgrade Bernstein Mkt Perform → Outperform $660
Dec-15-21Downgrade Bernstein Outperform → Mkt Perform $660
Dec-09-21Resumed Wells Fargo Overweight $750
Dec-07-21Resumed Cowen Market Perform $625
Dec-06-21Initiated Goldman Buy $824
Nov-19-21Resumed BMO Capital Markets Outperform $780
Nov-05-21Downgrade The Benchmark Company Buy → Hold
Jun-29-21Initiated H.C. Wainwright Buy $703
Jan-25-21Upgrade BMO Capital Markets Market Perform → Outperform $630
Jan-13-21Upgrade The Benchmark Company Hold → Buy $590
Jan-08-21Upgrade Citigroup Neutral → Buy $635 → $575
Oct-05-20Upgrade Cantor Fitzgerald Neutral → Overweight $690
Aug-20-20Downgrade The Benchmark Company Buy → Hold
Jul-09-20Upgrade SunTrust Hold → Buy $400 → $750
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Jan-21-22 01:38PM  
10:19AM  
09:38AM  
12:06AM  
Jan-20-22 01:38PM  
12:51PM  
12:00PM  
10:41AM  
10:39AM  
10:35AM  
09:38AM  
Jan-19-22 09:38PM  
10:27AM  
07:00AM  
12:59AM  
Jan-18-22 01:38PM  
01:38PM  
09:10AM  
Jan-17-22 09:20AM  
06:00AM  
Jan-14-22 12:10PM  
10:30AM  
10:16AM  
Jan-13-22 05:36PM  
04:05PM  
10:25AM  
08:30AM  
06:03AM  
Jan-12-22 10:42AM  
09:48AM  
Jan-11-22 11:13AM  
11:11AM  
10:24AM  
10:04AM  
09:02AM  
Jan-10-22 10:28AM  
10:19AM  
Jan-07-22 07:00AM  
Jan-06-22 06:00PM  
01:43PM  
Jan-05-22 11:27AM  
Dec-31-21 11:40AM  
Dec-30-21 05:45PM  
04:51AM  
Dec-29-21 02:16PM  
Dec-28-21 02:38AM  
02:38AM  
Dec-27-21 09:32AM  
Dec-25-21 01:38PM  
Dec-24-21 12:38PM  
08:00AM  
Dec-23-21 05:38PM  
04:38PM  
01:44PM  
01:43PM  
10:30AM  
09:30AM  
Dec-22-21 04:15PM  
10:08AM  
09:18AM  
Dec-21-21 05:45PM  
Dec-20-21 09:26AM  
Dec-18-21 08:38PM  
Dec-16-21 04:13PM  
01:27PM  
08:49AM  
07:57AM  
Dec-15-21 07:38PM  
09:29AM  
Dec-13-21 11:38PM  
07:38PM  
07:38PM  
05:45PM  
04:38PM  
10:54AM  
12:59AM  
Dec-11-21 08:15PM  
12:00PM  
04:38AM  
Dec-10-21 08:15PM  
08:20AM  
Dec-09-21 11:38PM  
07:38PM  
05:49PM  
05:22PM  
06:52AM  
Dec-08-21 05:29PM  
02:46AM  
Dec-07-21 02:00PM  
10:26AM  
Dec-06-21 05:38PM  
01:54PM  
09:40AM  
05:57AM  
Dec-03-21 10:00AM  
09:23AM  
09:20AM  
Dec-02-21 02:40PM  
02:23PM  
02:19PM  
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCourt MarionEVP CommercialJan 03Option Exercise342.931,000342,93020,644Jan 05 04:25 PM
McCourt MarionEVP CommercialJan 03Sale625.001,000625,00019,644Jan 05 04:25 PM
RYAN ARTHUR FDirectorJan 03Sale624.9510062,49522,391Jan 05 04:22 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 22Option Exercise221.08442,26797,775,8131,169,835Dec 23 04:29 PM
McCourt MarionEVP CommercialDec 13Sale653.12344224,67319,644Dec 14 04:05 PM
Landry Robert EEVP Finance CFODec 13Sale662.5011676,85029,260Dec 14 04:03 PM
Landry Robert EEVP Finance CFODec 10Option Exercise555.671,500833,50531,457Dec 14 04:03 PM
MURPHY ANDREW JEVP ResearchDec 10Sale666.277,1224,745,20259,167Dec 10 06:42 PM
Landry Robert EEVP Finance CFODec 10Sale666.42781520,47729,957Dec 10 05:37 PM
Tessier-Lavigne MarcDirectorDec 09Option Exercise371.403,7841,405,3785,862Dec 10 05:41 PM
Landry Robert EEVP Finance CFODec 09Option Exercise399.664,2501,698,55534,207Dec 10 05:37 PM
LAROSA JOSEPH JEVP General Counsel and SecretDec 09Option Exercise179.1330,0005,373,90046,520Dec 10 05:30 PM
MURPHY ANDREW JEVP ResearchDec 09Option Exercise52.0316,500858,49575,667Dec 10 06:42 PM
Tessier-Lavigne MarcDirectorDec 09Sale665.003,7842,516,3602,078Dec 10 05:41 PM
STAHL NEILEVP Research and DevelopmentDec 03Option Exercise179.1372,50012,986,925101,309Dec 06 04:10 PM
McCourt MarionEVP CommercialDec 01Option Exercise342.931,000342,93018,038Dec 02 04:04 PM
McCourt MarionEVP CommercialDec 01Sale639.131,000639,13017,038Dec 02 04:04 PM
RYAN ARTHUR FDirectorDec 01Sale637.5310063,75322,491Dec 02 04:07 PM
SING GEORGE LDirectorNov 22Sale657.502,0001,315,00029,858Nov 23 04:29 PM
SCHLEIFER LEONARD SPresident & CEONov 19Option Exercise221.08520,313115,030,120651,568Nov 19 05:50 PM
SING GEORGE LDirectorNov 19Sale655.001,000655,00031,858Nov 23 04:29 PM
SING GEORGE LDirectorNov 18Sale650.004,0002,600,00032,858Nov 18 04:09 PM
Landry Robert EEVP Finance CFONov 17Sale645.08681439,29925,986Nov 18 04:23 PM
Landry Robert EEVP Finance CFONov 16Option Exercise399.663,7501,498,72529,736Nov 18 04:23 PM
SING GEORGE LDirectorNov 16Sale650.00750487,5001,000Nov 18 04:09 PM
SING GEORGE LDirectorNov 16Sale656.266,0003,937,58036,858Nov 18 04:09 PM
MURPHY ANDREW JEVP ResearchNov 16Sale647.177,1674,638,26355,705Nov 17 04:04 PM
Van Plew Daniel PEVP & General Mgr, IndustrialNov 16Sale656.866,7784,452,19426,931Nov 17 04:02 PM
Van Plew Daniel PEVP & General Mgr, IndustrialNov 15Option Exercise270.4325,0006,760,75051,931Nov 17 04:02 PM
MURPHY ANDREW JEVP ResearchNov 15Option Exercise52.0316,579862,60572,284Nov 17 04:04 PM
McCourt MarionEVP CommercialNov 01Option Exercise342.931,000342,93018,038Nov 03 04:09 PM
RYAN ARTHUR FDirectorNov 01Sale642.5210064,25223,091Nov 03 04:11 PM
McCourt MarionEVP CommercialNov 01Sale640.001,000640,00017,038Nov 03 04:09 PM
McCourt MarionEVP CommercialOct 01Option Exercise342.931,000342,93018,038Oct 04 04:09 PM
RYAN ARTHUR FDirectorOct 01Sale569.4910056,94923,191Oct 04 04:10 PM
McCourt MarionEVP CommercialOct 01Sale576.751,000576,75017,038Oct 04 04:09 PM
COLES N ANTHONYDirectorSep 15Option Exercise365.9911,9484,372,80712,850Sep 17 04:01 PM
COLES N ANTHONYDirectorSep 15Sale658.9811,9487,873,484902Sep 17 04:01 PM
Zoghbi Huda YDirectorSep 14Option Exercise391.92998391,1361,889Sep 15 04:03 PM
Zoghbi Huda YDirectorSep 14Sale650.00998648,700891Sep 15 04:03 PM
Zoghbi Huda YDirectorSep 13Option Exercise391.922784893Sep 15 04:03 PM
Tessier-Lavigne MarcDirectorSep 13Option Exercise273.6712,7503,489,29214,828Sep 15 04:02 PM
BROWN MICHAEL SDirectorSep 13Option Exercise405.069,7043,930,68410,595Sep 15 04:03 PM
Zoghbi Huda YDirectorSep 13Sale651.1021,302891Sep 15 04:03 PM
Tessier-Lavigne MarcDirectorSep 13Sale641.7112,7508,181,8272,078Sep 15 04:02 PM
BROWN MICHAEL SDirectorSep 13Sale648.169,7046,289,792891Sep 15 04:03 PM
GOLDSTEIN JOSEPH LDirectorSep 10Option Exercise380.952,479944,3758,370Sep 13 04:01 PM
GOLDSTEIN JOSEPH LDirectorSep 10Sale650.002,4791,611,3505,891Sep 13 04:01 PM
McCourt MarionEVP CommercialSep 01Option Exercise342.931,000342,93018,038Sep 03 04:03 PM
RYAN ARTHUR FDirectorSep 01Sale676.2810067,62823,291Sep 03 04:04 PM
McCourt MarionEVP CommercialSep 01Sale674.721,000674,72017,038Sep 03 04:03 PM
Landry Robert EEVP Finance CFOAug 31Option Exercise555.671,000555,67026,903Sep 01 04:05 PM
SING GEORGE LDirectorAug 30Sale671.09550369,100750Aug 30 04:26 PM
SING GEORGE LDirectorAug 30Sale672.501,000672,50042,858Aug 30 04:26 PM
POON CHRISTINE ADirectorAug 27Option Exercise57.1115,000856,65016,681Aug 31 04:03 PM
POON CHRISTINE ADirectorAug 27Sale668.0915,00010,021,4061,681Aug 31 04:03 PM
SING GEORGE LDirectorAug 26Sale672.00150100,8001,000Aug 30 04:26 PM
VAGELOS P ROYDirectorAug 25Option Exercise179.1375,00013,434,750366,090Aug 27 04:01 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 23Sale661.843,4252,266,81713,182Aug 24 04:06 PM
Fenimore Christopher R.SVP ControllerAug 23Sale655.314,7813,133,03727,739Aug 24 04:04 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 20Option Exercise179.1310,0001,791,30023,182Aug 24 04:06 PM
Fenimore Christopher R.SVP ControllerAug 20Option Exercise179.1313,5002,418,25532,520Aug 24 04:04 PM
SCHLEIFER LEONARD SPresident & CEOAug 19Sale660.0310,0006,600,30021,178Aug 20 04:02 PM
COLES N ANTHONYDirectorAug 18Option Exercise345.475,1001,761,8976,002Aug 19 04:04 PM
SCHLEIFER LEONARD SPresident & CEOAug 18Sale650.03200,000130,006,000304,746Aug 20 04:02 PM
VAGELOS P ROYDirectorAug 18Sale650.0410,0396,525,75237,747Aug 19 04:05 PM
COLES N ANTHONYDirectorAug 18Sale650.005,1003,315,000902Aug 19 04:04 PM
COLES N ANTHONYDirectorAug 17Option Exercise345.47900310,9231,802Aug 19 04:04 PM
COLES N ANTHONYDirectorAug 17Sale650.00900585,000902Aug 19 04:04 PM
Bassler Bonnie LDirectorAug 16Option Exercise376.691,219459,1852,110Aug 17 04:16 PM
SCHLEIFER LEONARD SPresident & CEOAug 16Sale624.3610,0006,243,61431,178Aug 17 04:42 PM
SING GEORGE LDirectorAug 16Sale627.501,000627,5002,050Aug 17 04:17 PM
SING GEORGE LDirectorAug 16Sale630.00705444,15043,858Aug 17 04:17 PM
Bassler Bonnie LDirectorAug 16Sale630.001,219767,970891Aug 17 04:16 PM
YANCOPOULOS GEORGEPresident and Chief ScientificAug 16Sale625.2949,22730,781,138887,483Aug 17 04:13 PM
COLES N ANTHONYDirectorAug 13Option Exercise345.472,000690,9402,902Aug 16 04:04 PM
YANCOPOULOS GEORGEPresident and Chief ScientificAug 13Sale625.00773483,125936,710Aug 17 04:13 PM
COLES N ANTHONYDirectorAug 13Sale625.002,0001,250,000902Aug 16 04:04 PM
SING GEORGE LDirectorAug 13Sale620.00500310,00044,563Aug 13 05:19 PM
SING GEORGE LDirectorAug 12Sale611.001,000611,00045,063Aug 13 05:19 PM
SING GEORGE LDirectorAug 11Sale620.00300186,0003,050Aug 13 05:19 PM
SING GEORGE LDirectorAug 11Sale620.502,0001,241,00046,063Aug 13 05:19 PM
SING GEORGE LDirectorAug 10Sale613.852,6001,596,01048,063Aug 10 05:00 PM
Van Plew Daniel PEVP & General Mgr, IndustrialAug 10Sale611.866,6034,040,10526,931Aug 10 05:54 PM
Landry Robert EEVP Finance CFOAug 10Sale611.90537328,59325,903Aug 10 05:55 PM
Landry Robert EEVP Finance CFOAug 09Option Exercise381.923,0001,145,76028,903Aug 10 05:55 PM
Van Plew Daniel PEVP & General Mgr, IndustrialAug 09Option Exercise270.4325,0006,760,75051,931Aug 10 05:54 PM
BROWN MICHAEL SDirectorAug 09Sale612.381,6871,033,0857,662Aug 10 05:00 PM
Landry Robert EEVP Finance CFOAug 09Sale617.83364224,89125,903Aug 10 05:55 PM
Landry Robert EEVP Finance CFOAug 06Option Exercise381.922,000763,84027,903Aug 10 05:55 PM
SCHLEIFER LEONARD SPresident & CEOAug 06Option Exercise52.03400,00020,812,000596,176Aug 10 05:05 PM
SING GEORGE LDirectorAug 06Sale612.42350214,3473,350Aug 10 05:00 PM
SING GEORGE LDirectorAug 06Sale611.384,0002,445,52050,663Aug 10 05:00 PM
Bassler Bonnie LDirectorAug 05Option Exercise391.922,5591,002,9233,450Aug 06 04:02 PM
YANCOPOULOS GEORGEPresident and Chief ScientificAug 05Sale600.0650,00030,003,000937,483Aug 06 04:03 PM
Bassler Bonnie LDirectorAug 05Sale600.002,5591,535,400891Aug 06 04:02 PM
McCourt MarionEVP CommercialAug 02Option Exercise342.931,000342,93018,038Aug 04 04:03 PM
RYAN ARTHUR FDirectorAug 02Sale577.9510057,79523,391Aug 04 04:05 PM
McCourt MarionEVP CommercialAug 02Sale577.121,000577,12017,038Aug 04 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretJul 06Sale580.003,3981,970,84013,182Jul 07 04:01 PM